In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Wright Medical Back on Track?

Executive Summary

Wright Medical hasn’t enjoyed the smoothest ride over the past 15 years, a stretch that included a spin-out, debt problems, and a buyout, as well as an IPO. All the while, though, the company has proven to be an innovator in the large joints industries and now—under new CEO Gary Henley—it is establishing itself as a force in the extremities and biomaterials markets.
Advertisement

Related Content

Ascension Orthopedics' Fate May Rest on the Shoulder
Ortho VCs Are Getting Soft, But Still Show Spine
Orthopedics Settlement: Puts the Issue to Bed--Or Does It?
Joint Resurfacing: Boom or Bust?
Tornier: Building an Extremities Play in Orthopedics
New Ceramic Approval Boosts Wright Medical
Building Platforms in Orthopedics
Wright Medical and Cremascoli Ortho: Crossing Paths
Righting Wright Medical
Wright Medical: Surviving as a Mid-Sized Device Company

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel